Grant H. Skrepnek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Grant H. Skrepnek has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Matthew C. Dickson
College of Pharmacy, The University of Oklahoma Health Sciences, Oklahoma City, OK 73117, USA
5 shared publications David G. Armstrong
Division of Vascular and Endovascular Surgery and Southern Arizona Limb Salvage Alliance, Department of Surgery, University of Arizona College of Medicine, Tucson, AZ
4 shared publications- Joseph L. Mills
Baylor College of Medicine
4 shared publications - Paul M. Boylan
The University of Oklahoma Harold Hamm Health Campus College of Pharmacy , Oklahoma City, OK
3 shared publications - Ahmed Essam Altyar
Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
2 shared publications Laura M. Tidmore
The University of Oklahoma Health Science Center, Oklahoma, OK
2 shared publications
Latest Publications
- 17 September 2026
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (6)
A financial equilibrium analysis of the publicly traded U.S. pharmacy sector, 2010–2024
- 17 September 2026
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (6)
A financial equilibrium analysis of the publicly traded U.S. pharmacy sector, 2010–2024
- Open Access
- 7 August 2026
- Published by MDPI AG in Health Economics and Policy
- Vol. 1 (1) , 1
The Foundation of Health Economics and Policy
Prior to the 1960s, the topic of health and health care lacked precise formality and integration in economic terms, though it bore a general consensus that the sector departed from other markets in very unique and disparate ways
- 7 August 2026
- Published by MDPI AG in Health Economics and Policy
- Vol. 1 (1) , 1
Open AccessThe Foundation of Health Economics and Policy
Prior to the 1960s, the topic of health and health care lacked precise formality and integration in economic terms, though it bore a general consensus that the sector departed from other markets in very unique and disparate ways
- 9 July 2026
- Published by Springer Nature
- p. 3788-3800
Parents with Borderline Personality Disorder
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Geriatric Pharmacology
- Vol. 3 (1)
Montelukast deprescribing and neuropsychiatric events in older adults: a cross-sectional descriptive report
- 1 February 2026
- Published by Taylor & Francis in Geriatric Pharmacology
- Vol. 3 (1)
Open AccessMontelukast deprescribing and neuropsychiatric events in older adults: a cross-sectional descriptive report
- 20 January 2026
- Published by Springer Nature
- p. 1-12
Parents with Borderline Personality Disorder
- 14 March 2025
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 17 (6) , 102326
Experience using a state board of pharmacy adequate staffing form: A descriptive report
- 14 March 2025
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 17 (6) , 102326
Experience using a state board of pharmacy adequate staffing form: A descriptive report
- Open Access
- 17 September 2024
- Published by Elsevier in Exploratory Research in Clinical and Social Pharmacy
- Vol. 16, 100509
Montelukast deprescribing in outpatient specialty clinics: A single center cross-sectional study
- 17 September 2024
- Published by Elsevier in Exploratory Research in Clinical and Social Pharmacy
- Vol. 16, 100509
Open AccessMontelukast deprescribing in outpatient specialty clinics: A single center cross-sectional study
- Open Access
- 10 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (18) , 5361
Hospitalization and Health Resource Utilization in Emergency Department Cases of Diabetic Foot Infections in the U.S. from 2012 to 2021: A Nationally Representative Analysis
Objectives: The objective of this paper was to assess hospitalizations and health resource utilization associated with diabetic foot infection (DFI)-related visits within emergency departments (EDs) in the U.S. Methods: This nationally representative, cross-sectional historical cohort utilized the Centers for Disease Control and Prevention’s (CDC’s) National Hospital Ambulatory Medical Care Survey across a ten-year period from 2012 to 2021. Inclusion criteria were as follows: adults ≥18 years of age; a diagnosis of Type 1 or Type 2 diabetes mellitus; presence of a DFI. Comparisons were drawn relative to a cohort of patients with diabetes without foot complications. Study outcomes included 72-hour (72 h) ED revisit, hospitalization, and length of stay (LOS). Top diagnoses and medications were also reported. Multivariable, generalized, linear regression analyses were employed, controlling for key demographics, health system factors, clinical characteristics, and year. Results: An estimated 150.6 million ED visits included a diabetes diagnosis, with 2.4 million involving a DFI (1.6%). Approximately half of DFI cases were hospitalized (43.7%). Anti-infective medications were prescribed in 83.1% of DFI cases, including vancomycin in 28.1%. Multivariable analyses observed that DFIs were associated with a 3.002 times higher odds of hospital admissions (CI: 2.145–4.203, p < 0.001) and a 55.0% longer LOS (IR = 1.550, CI: 1.241–1.936, p < 0.001). DFIs were not significantly associated with a 72 h ED revisit. Conclusions: This nationally representative study of 2.4 million DFI-related ED visits in the U.S. observed higher odds of hospital admissions and a longer LOS for DFIs versus diabetes without foot complications. Continued research should seek to assess prevention and coordinated treatment interventions prior to the emergence of DFIs requiring ED care.
- 10 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (18) , 5361
Open AccessHospitalization and Health Resource Utilization in Emergency Department Cases of Diabetic Foot Infections in the U.S. from 2012 to 2021: A Nationally Representative Analysis
Objectives: The objective of this paper was to assess hospitalizations and health resource utilization associated with diabetic foot infection (DFI)-related visits within emergency departments (EDs) in the U.S. Methods: This nationally representative, cross-sectional historical cohort utilized the Centers for Disease Control and Prevention’s (CDC’s) National Hospital Ambulatory Medical Care Survey across a ten-year period from 2012 to 2021. Inclusion criteria were as follows: adults ≥18 years of age; a diagnosis of Type 1 or Type 2 diabetes mellitus; presence of a DFI. Comparisons were drawn relative to a cohort of patients with diabetes without foot complications. Study outcomes included 72-hour (72 h) ED revisit, hospitalization, and length of stay (LOS). Top diagnoses and medications were also reported. Multivariable, generalized, linear regression analyses were employed, controlling for key demographics, health system factors, clinical characteristics, and year. Results: An estimated 150.6 million ED visits included a diabetes diagnosis, with 2.4 million involving a DFI (1.6%). Approximately half of DFI cases were hospitalized (43.7%). Anti-infective medications were prescribed in 83.1% of DFI cases, including vancomycin in 28.1%. Multivariable analyses observed that DFIs were associated with a 3.002 times higher odds of hospital admissions (CI: 2.145–4.203, p < 0.001) and a 55.0% longer LOS (IR = 1.550, CI: 1.241–1.936, p < 0.001). DFIs were not significantly associated with a 72 h ED revisit. Conclusions: This nationally representative study of 2.4 million DFI-related ED visits in the U.S. observed higher odds of hospital admissions and a longer LOS for DFIs versus diabetes without foot complications. Continued research should seek to assess prevention and coordinated treatment interventions prior to the emergence of DFIs requiring ED care.
- 1 January 2024
- Published by Springer Nature
- p. 1-10
Real-World Evidence and Outcomes Associated with Pharmacotherapy in Schizophrenia
- 1 January 2024
- Published by Springer Nature
- p. 1-10
Real-World Evidence and Outcomes Associated with Pharmacotherapy in Schizophrenia
- Open Access
Association between Priority Conditions and Access to Care, Treatment of an Ongoing Condition, and Ability to Obtain Prescription Medications among Medicare Beneficiaries during the COVID-19 Pandemic
Several comorbid conditions have been observed to be associated with an increased risk of poor outcomes following a diagnosis of COVID-19. The purpose of this investigation was to assess associations between Centers for Medicare and Medicaid Services (CMS) designated priority conditions and an inability to access care, treat ongoing conditions, and obtain prescription medications among Medicare beneficiaries in the United States during the COVID-19 pandemic. Nationally representative CMS Medicare Current Beneficiary Survey (MCBS) COVID-19 Supplement Public Use Files (PUF) were analyzed via bivariable, binomial generalized linear models across three time periods: (1) Summer 2020; (2) Fall 2020; and (3) Winter 2021. Across an estimated 55.3–57.4 million Medicare beneficiaries, approximately one-fifth reported an inability to access at least one type of care at the onset of the pandemic. Significantly worse odds of an ability to get care across various time periods was observed among several priority conditions including immune disorders, cancer, depression, osteoporosis, diabetes, arthritis, and numerous cardiovascular and pulmonary conditions. Among those reporting an inability to access care, approximately one-third involved treatment of an ongoing condition, and under one-tenth involved prescription medications. To identify modifiable risk factors and to develop active interventions, future work should continue to assess the complex associations between outcomes, access to care, comorbidities, evolving healthcare infrastructures, computerization, and various public health initiatives.
Open AccessAssociation between Priority Conditions and Access to Care, Treatment of an Ongoing Condition, and Ability to Obtain Prescription Medications among Medicare Beneficiaries during the COVID-19 Pandemic
Several comorbid conditions have been observed to be associated with an increased risk of poor outcomes following a diagnosis of COVID-19. The purpose of this investigation was to assess associations between Centers for Medicare and Medicaid Services (CMS) designated priority conditions and an inability to access care, treat ongoing conditions, and obtain prescription medications among Medicare beneficiaries in the United States during the COVID-19 pandemic. Nationally representative CMS Medicare Current Beneficiary Survey (MCBS) COVID-19 Supplement Public Use Files (PUF) were analyzed via bivariable, binomial generalized linear models across three time periods: (1) Summer 2020; (2) Fall 2020; and (3) Winter 2021. Across an estimated 55.3–57.4 million Medicare beneficiaries, approximately one-fifth reported an inability to access at least one type of care at the onset of the pandemic. Significantly worse odds of an ability to get care across various time periods was observed among several priority conditions including immune disorders, cancer, depression, osteoporosis, diabetes, arthritis, and numerous cardiovascular and pulmonary conditions. Among those reporting an inability to access care, approximately one-third involved treatment of an ongoing condition, and under one-tenth involved prescription medications. To identify modifiable risk factors and to develop active interventions, future work should continue to assess the complex associations between outcomes, access to care, comorbidities, evolving healthcare infrastructures, computerization, and various public health initiatives.